SUCCOR cone study: conization before radical hysterectomy.


Journal

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
ISSN: 1525-1438
Titre abrégé: Int J Gynecol Cancer
Pays: England
ID NLM: 9111626

Informations de publication

Date de publication:
02 2022
Historique:
received: 28 02 2021
accepted: 06 12 2021
pubmed: 19 1 2022
medline: 12 3 2022
entrez: 18 1 2022
Statut: ppublish

Résumé

To evaluate disease-free survival of cervical conization prior to radical hysterectomy in patients with stage IB1 cervical cancer (International Federation of Gynecology and Obstetrics (FIGO) 2009). A multicenter retrospective observational cohort study was conducted including patients from the Surgery in Cervical Cancer Comparing Different Surgical Aproaches in Stage IB1 Cervical Cancer (SUCCOR) database with FIGO 2009 IB1 cervical carcinoma treated with radical hysterectomy between January 1, 2013, and December 31, 2014. We used propensity score matching to minimize the potential allocation biases arising from the retrospective design. Patients who underwent conization but were similar for other measured characteristics were matched 1:1 to patients from the non-cone group using a caliper width ≤0.2 standard deviations of the logit odds of the estimated propensity score. We obtained a weighted cohort of 374 patients (187 patients with prior conization and 187 non-conization patients). We found a 65% reduction in the risk of relapse for patients who had cervical conization prior to radical hysterectomy (hazard ratio (HR) 0.35, 95% confidence interval (CI) 0.16 to 0.75, p=0.007) and a 75% reduction in the risk of death for the same sample (HR 0.25, 95% CI 0.07 to 0.90, p=0.033). In addition, patients who underwent minimally invasive surgery without prior conization had a 5.63 times higher chance of relapse compared with those who had an open approach and previous conization (HR 5.63, 95% CI 1.64 to 19.3, p=0.006). Patients who underwent minimally invasive surgery with prior conization and those who underwent open surgery without prior conization showed no differences in relapse rates compared with those who underwent open surgery with prior cone biopsy (reference) (HR 1.94, 95% CI 0.49 to 7.76, p=0.349 and HR 2.94, 95% CI 0.80 to 10.86, p=0.106 respectively). In this retrospective study, patients undergoing cervical conization before radical hysterectomy had a significantly lower risk of relapse and death.

Identifiants

pubmed: 35039455
pii: ijgc-2021-002544
doi: 10.1136/ijgc-2021-002544
doi:

Types de publication

Journal Article Multicenter Study Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

117-124

Investigateurs

Nabil Abdalla (N)
Sedat Akgöl (S)
Demirkiran Aksahin (D)
Shamistan Aliyev (S)
Maria Alonso-Espias (M)
Igor Aluloski (I)
Claudia Andrade (C)
Nikola Badzakov (N)
Rosa Barrachina (R)
Giorgio Bogani (G)
Eduard-Aexandru Bonci (EA)
Hélène Bonsang-Kitzis (H)
Cosima Brucker (C)
Laura Cárdenas (L)
Andrea Casajuana (A)
Pere Cavalle (P)
Jorge Cea (J)
Benito Chiofalo (B)
Gloria Cordeiro (G)
Pluvio Coronado (P)
Maria Cuadra (M)
Javier Díez (J)
Teresa Diniz da Costa (TDD)
Santiago Domingo (S)
Lukas Dostalek (L)
Fuat Elif (F)
Diego Erasun (D)
Mathias Fehr (M)
Sergi Fernandez-Gonzalez (S)
Annamaria Ferrero (A)
Soledad Fidalgo (S)
Gabriel Fiol (G)
Khadra Galaal (K)
José García (J)
Gerhard Gebauer (G)
Fabio Ghezzi (F)
Juan Gilabert (J)
Nana Gomes (N)
Elisabete Gonçalves (E)
Virginia Gonzalez (V)
Frederic Grandjean (F)
Miriam Guijarro (M)
Frédéric Guyon (F)
Jolien Haesen (J)
Gines Hernandez-Cortes (G)
Sofía Herrero (S)
Imre Pete (I)
Ioannis Kalogiannidis (I)
Erbil Karaman (E)
Andreas Kavallaris (A)
Lukasz Klasa (L)
Ioannis Kotsopoulos (I)
Stefan Kovachev (S)
Uppin Arno Leht (UA)
Arantxa Lekuona (A)
Mathieu Luyckx (M)
Michael Mallmann (M)
Gemma Mancebo (G)
Aljosa Mandic (A)
Tiermes Marina (T)
Victor Martin (V)
María Belén Martín-Salamanca (MB)
Víctor Lago (V)
Alejandra Martinez (A)
Gesine Meili (G)
Gustavo Mendinhos (G)
Liliana Mereu (L)
Milena Mitrovic (M)
Sara Morales (S)
Enrique Moratalla (E)
Natalia R Gómez-Hidalgo (NR)
Bibiana Morillas (B)
Eva Myriokefalitaki (E)
Maja PakižImre (M)
Imre Pete (I)
Stamatios Petousis (S)
Laurentiu Pirtea (L)
Natalia Povolotskaya (N)
Sonia Prader (S)
Alfonso Quesada (A)
Mikuláš Redecha (M)
Fernando Roldan (F)
Philip Rolland (P)
Reeli Saaron (R)
Cosmin-Paul Sarac (CP)
Jens-Peter Scharf (JP)
Špela Smrkolj (Š)
Rita Sousa (R)
Artem Stepanyan (A)
Vladimír Študent (V)
Carmen Tauste (C)
Hans Trum (H)
Taner Turan (T)
Manuela Undurraga (M)
Alicia Vázquez (A)
Ignace Vergote (I)
George Vorgias (G)
Ignacio Zapardiel (I)

Commentaires et corrections

Type : CommentIn

Informations de copyright

© IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Enrique Chacon (E)

Gynecologic Oncology, Universidad de Navarra, Pamplona, Navarra, Spain.

Nabil Manzour (N)

Clinica Universidad de Navarra Departamento de Ginecologia y Obstetricia, Pamplona, Navarra, Spain.

Vanna Zanagnolo (V)

Istituto Europeo di Oncologia, Milano, Anognnn, Italy.

Denis Querleu (D)

Surgery, Institut Bergonie, Bordeaux, France.

Jorge M Núñez-Córdoba (JM)

Clinica Universidad de Navarra, Pamplona, Navarra, Spain.

Nerea Martin-Calvo (N)

Department of Preventive Medicine and Public Health, Universidad de Navarra, Pamplona, Spain.

Mihai Emil Căpîlna (ME)

Emergency County Hospital Targu-Mures, Targu Mures, Romania.

Anna Fagotti (A)

University Hospital Agostino Gemelli Gynaecological Oncology Complex Operative Unit, Roma, Lazio, Italy.

Ali Kucukmetin (A)

Queen Elizabeth Hospital, Gateshead, Gateshead, UK.

Constantijne Mom (C)

Amsterdam University Medical Centres, Amsterdam, Noord-Holland, Netherlands.

Galina Chakalova (G)

University Oncologic Hospital, Sofia, Bulgaria.

Aliyev Shamistan (A)

National Center of Oncology, Baku, Azerbaijan.

Antonio Gil Moreno (A)

Gynecology, Vall d'Hebron Hospital, Sant Cugat Del Vallés, Barcelona, Spain.
Universitat Autònoma de Barcelona, Barcelona, Barcelona, Spain.

Mario Malzoni (M)

Endoscopica Malzoni, Center for Advanced Endoscopic Gynecologic Surgery, Center for Advanced Endoscopic Gynecologic Surgery, Avellino, Italy.

Fabrice Narducci (F)

Department of Gynecology, Centre Oscar Lambret, Lille, France.

Octavio Arencibia (O)

University Maternal Hospital Canary Islands, Las Palma, Spain.

Francesco Raspagliesi (F)

Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Lombardia, Italy.

Tayfun Toptas (T)

Gynecologic Oncology, Saglik Bilimleri University Antalya Research and Training Hospital, Antalya, Turkey.

David Cibula (D)

Department of Obstetrics and Gynecology, University of Prague, Prague, Czech Republic.

Dilyara Kaidarova (D)

Oncogynecology, Kazahskij Naucno-issledovatel'skij Institut Onkologii i Radiologii, Almaty, Kazakhstan.

Mehmet Mutlu Meydanli (MM)

Department of Gynecologic Oncology, Zekai Tahir Burak Women's Health Education and Research Hospital, Ankara, Turkey.

Mariana Tavares (M)

IPO-PORTO, Porto, Porto, Portugal.

Dmytro Golub (D)

Department of Surgery, LISOD-Israeli Oncological Hospital, Kyiv, Ukraine.

Anna Myriam Perrone (AM)

Azienda Ospedaliero-Universitaria di Bologna Policlinico SantOrsola-Malpighi, Bologna, Italy.

Robert Poka (R)

Obstetrics and Gynecology, Unit of Gynecologic Oncology, Institute of Obstetrics and Gynecology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.

Dimitrios Tsolakidis (D)

General Hospital of Thessaloniki Papageorgiou, Thessaloniki, Central Macedonia, Greece.

Goran Vujić (G)

Clinical Hospital Center, Zagreb, Croatia.

Marcin A Jedryka (MA)

Oncological Gynecology, Lower Silesian Cancer Center, Wroclaw, Poland.

Petra L M Zusterzeel (PLM)

Gynecological Oncology, Radboudumc, Nijmegen, Netherlands.

Jogchum Jan Beltman (JJ)

Gynaecology, LUMC, Leiden, Netherlands.

Frederic Goffin (F)

Obstetrics and Gynecology, University of Liege, Liege, Belgium.

Dimitrios Haidopoulos (D)

Division of Gynecologic Oncology, 1st Department of Obstetrics and Gynecology, Alexandra Hospital, National and Kapodistrian University of Athens, Athens, Greece.

Herman Haller (H)

Clinical Hospital Center Rijeka, Rijeka, Croatia.

Robert Jach (R)

Department of Gynecology and Oncology, Jagiellonian University, Krakow, Poland.

Iryna Yezhova (I)

Lviv Oncology Center, Lviv, Ukraine.

Igor Berlev (I)

North-Western State Medical University, NN Petrov Research Institute of Oncology, Saint-Petersburg, Saint-Petersburg, Russian Federation.

Margarida Bernardino (M)

Gynecology, Instituto Português de Oncologia de Lisboa, Lisboa, Lisboa, Portugal.

Rasiah Bharathan (R)

University Hospitals of Leicester NHS Trust, Leicester, Leicester, UK.

Maximilian Lanner (M)

Kardinal Schwarzenberg'sches Krankenhaus, Schwarzach, Steiermark, Austria.

Minna M Maenpaa (MM)

Obstetrics and Gynecology, Tampere University Hospital, Tampere, Finland.

Vladyslav Sukhin (V)

Oncogynecology, Grigorev Institute for Radiology, Kharkiv, Ukraine.

Jean-Guillaume Feron (JG)

Institut Curie, Paris, Île-de-France, France.

Robert Fruscio (R)

Department of Medicine and Surgery, University of Milan-Bicocca, Milano, Italy.
Clinic of Obstetrics and Gynecology, Hospital San Gerardo, Monza, Italy.

Kersti Kukk (K)

North Estonia Medical Centre, Tallinn, Estonia.

Jordi Ponce (J)

Bellvitge University Hospital, L'Hospitalet de Llobregat, Catalunya, Spain.

Jose Angel Minguez (JA)

Gynecology, Clinica Universitaria de Navarra, Pamplona, Navarra, Spain.

Daniel Vázquez-Vicente (D)

Gynecology, Clinica Universitaria de Navarra, Madrid, Spain.

Teresa Castellanos (T)

Gynecology, Clinica Universitaria de Navarra, Madrid, Spain.

Felix Boria (F)

Clinica Universidad de Navarra Departamento de Ginecologia y Obstetricia, Madrid, Spain.

Juan Luis Alcazar (JL)

Obstetrics and Gynecology, School of Medicine, University of Navarra, Pamplona, Spain.

Luis Chiva (L)

Obstetrics and Gynecology, Clinica Universidad de Navarra, Madrid, Spain lchiva@unav.es.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH